Source: International Congress 2018 – Innovative therapies in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Wenzel (Pittsburgh, PA, United States of America), G. Brusselle (Ghent, Belgium), I. Hirsch (Gaithersburg, MD, United States of America), J. Zangrilli (Gaithersburg, MD, United States of America), S. Rastogi (Gaithersburg, MD, United States of America). Benralizumab efficacy in patients with uncontrolled eosinophilic asthma by age at diagnosis. 603

Member's Comments

No comment yet.

Related content which might interest you: The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Clinical profile of patients with adult-onset eosinophilic asthma Source: ERJ Open Res 2016: 00100-2015 Year: 2016 Re-evaluation of asthma diagnosis in patients with adult-onset asthma Source: International Congress 2017 – New research in asthma and COPD Year: 2017 The effect of smoking on exacerbation risk in eosinophilic patients with COPD Source: Eur Respir J, 50 (6) 1702086; 10.1183/13993003.02086-2017 Year: 2017 The effect of smoking on exacerbation risk in eosinophilic patients with COPD Source: Eur Respir J, 50 (6) 1701820; 10.1183/13993003.01820-2017 Year: 2017 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Impact of age, age at diagnosis and duration of asthma on the risk of exacerbations in the EuroSMART study Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Clinical outcomes in non-eosinophilic versus eosinophilic asthma after 12 months specialist management Source: International Congress 2018 – Clinical markers of asthma Year: 2018 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Asthma in adults: association of asthma symptoms and age at asthma diagnosis Source: Virtual Congress 2020 – Risk factors for chronic lung diseases Year: 2020 Sputum eosinophilia in the diagnosis and management of asthma of moderate severity in adults Source: Eur Respir J 2007; 30: Suppl. 51, 587s Year: 2007 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021